Don’t Bogart That Labeling – Cesamet “Not Approvable”
Launch of Valeant’s cannabinoid agonist for chemotherapy-induced emesis, which had been marketed by Lilly before 2004, remains on hold as FDA seeks more information on adverse events.
Launch of Valeant’s cannabinoid agonist for chemotherapy-induced emesis, which had been marketed by Lilly before 2004, remains on hold as FDA seeks more information on adverse events.